SANA -Sana Biotechnology, Inc.

Name : Sana Biotechnology, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $0.0000

EPSttm :

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=SANA #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=SANA &conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]

Float Short %

32.16

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

0.03

EPS Last/This Y

0.28

EPS This/Next Y

0.11

Price

1.77

Target Price

10.43

Analyst Recom

1.22

Performance Q

-51.91

Relative Volume

1.19

Beta

1.75

Ticker: SANA

23 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-12	SANA	2.92	0.21	0.01	27975
2025-03-13	SANA	2.65	0.19	0.11	30223
2025-03-14	SANA	2.92	0.19	0.91	30324
2025-03-17	SANA	2.76	0.19	0.04	30355
2025-03-18	SANA	2.27	0.19	0.44	30671
2025-03-19	SANA	2.34	0.19	0.08	31051
2025-03-20	SANA	2.25	0.19	0.66	30919
2025-03-21	SANA	2.34	0.19	6.80	31012
2025-03-24	SANA	2.43	0.26	0.13	20971
2025-03-25	SANA	2.15	0.26	0.39	21100
2025-03-26	SANA	1.82	0.25	0.24	21713
2025-03-27	SANA	1.85	0.24	2.35	22647
2025-03-28	SANA	1.7	0.25	0.03	22913
2025-03-31	SANA	1.7	0.24	0.14	23595
2025-04-01	SANA	1.495	0.24	0.07	23796
2025-04-02	SANA	1.625	0.24	0.35	24179
2025-04-03	SANA	1.365	0.24	0.22	24320
2025-04-04	SANA	1.49	0.24	0.64	24321
2025-04-07	SANA	1.53	0.24	0.30	24471
2025-04-08	SANA	1.34	0.23	0.14	24482
2025-04-09	SANA	1.545	0.21	0.49	24123
2025-04-10	SANA	1.54	0.21	0.08	24083
2025-04-11	SANA	1.765	0.21	0.11	24094
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-12	SANA	2.92	24.5	104.4	-1.14
2025-03-13	SANA	2.65	24.5	139.5	-1.14
2025-03-14	SANA	2.93	24.5	94.4	-1.14
2025-03-17	SANA	2.77	30.6	131.0	-1.14
2025-03-18	SANA	2.28	30.6	159.6	-1.14
2025-03-19	SANA	2.34	30.6	73.1	-1.14
2025-03-20	SANA	2.26	30.6	37.7	-1.14
2025-03-21	SANA	2.32	30.6	20.9	-0.88
2025-03-24	SANA	2.42	37.5	15.3	-0.88
2025-03-25	SANA	2.15	37.5	58.8	-0.88
2025-03-26	SANA	1.81	37.5	72.3	-0.88
2025-03-27	SANA	1.84	37.5	23.4	-0.88
2025-03-28	SANA	1.71	37.5	48.8	-0.88
2025-03-31	SANA	1.68	37.5	33.5	-0.88
2025-04-01	SANA	1.50	37.5	58.9	-0.88
2025-04-02	SANA	1.63	37.5	2.7	-0.88
2025-04-03	SANA	1.37	37.5	74.8	-0.88
2025-04-04	SANA	1.48	37.5	3.8	-0.88
2025-04-07	SANA	1.54	37.5	18.2	-0.88
2025-04-08	SANA	1.34	37.5	64.6	-0.88
2025-04-09	SANA	1.55	37.5	-19.1	-0.88
2025-04-10	SANA	1.54	37.5	29.4	-0.88
2025-04-11	SANA	1.77	37.5	-18.0	-0.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

23 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-12	SANA	-0.59	3.28	33.80
2025-03-13	SANA	-0.59	3.28	33.80
2025-03-14	SANA	-0.59	3.28	33.80
2025-03-17	SANA	-0.59	3.28	33.80
2025-03-18	SANA	-0.59	3.28	33.82
2025-03-19	SANA	-0.59	3.28	33.82
2025-03-20	SANA	-0.59	3.28	33.82
2025-03-21	SANA	-0.59	3.28	33.82
2025-03-24	SANA	-0.59	3.26	33.56
2025-03-25	SANA	-0.59	3.26	33.56
2025-03-26	SANA	-0.59	3.26	31.87
2025-03-27	SANA	-0.29	3.26	31.87
2025-03-28	SANA	-0.29	3.26	31.87
2025-03-31	SANA	-0.29	3.26	31.87
2025-04-01	SANA	-0.29	3.26	31.87
2025-04-02	SANA	-0.29	3.26	31.87
2025-04-03	SANA	-0.29	3.26	31.87
2025-04-04	SANA	-0.29	3.26	31.87
2025-04-07	SANA	-0.29	3.26	31.87
2025-04-08	SANA	-0.29	3.26	31.87
2025-04-09	SANA	-0.29	3.26	31.87
2025-04-10	SANA	-0.29	3.26	32.16
2025-04-11	SANA	-0.29	3.26	32.16
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

23 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=SANA 589 360 ]

Last Quarter Act. EPS

-0.23

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

-0.29

Institutional Transactions

3.26

Beta

1.75

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

10.43

P/E

Forward P/E

PEG

P/S

P/B

1.57

P/Free Cash Flow

EPS

-1.17

Average EPS Est. Cur. Y

-0.88

EPS Next Y. (Est.)

-0.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.19

Return on Equity vs Sector %

-126.1

Return on Equity vs Industry %

-113.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

-18

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=SANA 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=SANA 589 450 ]

Sana Biotechnology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 194

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

stock quote shares SANA -Sana Biotechnology, Inc. Stock Price stock today

news today SANA -Sana Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SANA -Sana Biotechnology, Inc. yahoo finance google finance

stock history SANA -Sana Biotechnology, Inc. invest stock market

stock prices SANA premarket after hours

ticker SANA fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

SANA -Sana Biotechnology, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SANA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y